ANTX AN2 Therapeutics, Inc.
Financings ·
AN2 Therapeutics filed an $80,000,000 prospectus supplement dated April 20, 2026 for sales through Jefferies LLC, which will be deemed an underwriter, earns up to 3.0% of gross proceeds and is under no obligation to sell any set amount.
AN2 Therapeutics set up an $80 million at-the-market sales program with Jefferies LLC on April 9, 2026 and ended an earlier agreement with TD Securities, against a 2025 net loss of $35.2 million and cash used in operations of $29.8 million.
The company is selling 8,245,611 shares and pre-funded warrants for up to 5,789,493 shares to institutional investors. Leerink Partners is the exclusive placement agent, and closing is expected March 10, 2026.
AN2 Therapeutics swapped 2,500,000 and 300,000 common shares for pre-funded warrants held by Coastlands Capital Partners LP on June 17 and June 19, 2025, and the 8-K reports no cash to the company from either exchange.
AN2 Therapeutics says the Phase 3 portion of its EBO-301 study missed its primary endpoint, and it projects $78.5 million in cash lasting into 2028 while it shifts to Chagas, melioidosis and oncology programs that have no human efficacy data yet.
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from its boron chemistry platform. Its development pipeline spans hematologic diseases, infectious diseases and oncology, with three Phase 2 studies expected to initiate in 2026, two preclinical candidates, and advanced research programs focused on targets in oncology, bone disorders and infectious diseases. Its initial product candidate is oral epetraborole. In March 2026, the company announced a plan to expand development of epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). The company describes PV as a blood cancer characterized by overproduction of red blood cells in the bone marrow, which can lead to serious complications including arterial and venous thromboembolic events. The company states that it is committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
| Product or program | What it is | Stage |
|---|---|---|
| Epetraborole | Oral small molecule being studied in phlebotomy-dependent polycythemia vera | Phase 2 proof-of-concept planned |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $24.8 million | $40.5 million |
| Net income (loss) | -$35.2 million | -$51.3 million |
| Cash from operations | -$29.8 million | -$49.3 million |
| Cash and equivalents | $19.9 million | $21.4 million |
| Short-term investments | $38.1 million | $62.3 million |
Our latest story on this, dated Apr 9, 2026: "AN2 Therapeutics sets up $80 million at-the-market program with Jefferies". The story links the filing or release it is based on. Read the story.
AN2 Therapeutics, Inc. trades under the ticker ANTX on NASDAQ.
AN2 Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for AN2 Therapeutics, Inc. is 1880438. Its filings are on SEC EDGAR.
37,736,237 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Our directory records AN2 Therapeutics, Inc. under United States.
Our directory classifies AN2 Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for AN2 Therapeutics, Inc. is US0373261058.
aibio.space lists AN2 Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from its boron chemistry platform. Its development pipeline spans hematologic diseases, infectious diseases and oncology, with three Phase 2 studies expected to initiate in 2026, two preclinical candidates, and advanced research programs focused on targets in oncology, bone disorders and infectious diseases.
Epetraborole: Oral small molecule being studied in phlebotomy-dependent polycythemia vera Stage: Phase 2 proof-of-concept planned.
AN2 Therapeutics, Inc. reported a net loss of $35.2 million for the fiscal year ended Dec 31, 2025, and used $29.8 million of cash in operations, per its annual report to the SEC.
$24.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$78.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio